Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocertatug Rezetecan in Combination With Anti-Cancer Agents in Advanced Solid Tumors
NCT06796907Phase 2Recruiting
- Sponsor
- GSK
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 23
01
Overview
A Phase 2 trial of mocertatug rezetecan in endometrial cancer (EC), ovarian cancer, sponsored by GSK. Started Mar 2025; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
endometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on NCT06796907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06796907.